At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,099 enrolled
Drug / intervention
Travoprost ophthalmic solution, 0.003% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003% Compared to TRAVATAN in Patients With Open-Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Travoprost ophthalmic solution, 0.003% and Travoprost ophthalmic solution, 0.004% for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 1,099 participants.
Detailed Summary
The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartNov 2011
Primary CompletionAug 2012
TodayJul 2026
First PostedOct 18, 2011
Enrollment StartNov 1, 2011
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.7 years ago
Interventions
Travoprost ophthalmic solution, 0.003%drug
Travoprost ophthalmic solution, 0.004%drug